{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:14:49Z","timestamp":1779909289712,"version":"3.53.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Euan MacDonald Centre for Motor Neurone Disease Research"},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R001162\/1"],"award-info":[{"award-number":["MR\/R001162\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Up to 50% of people with amyotrophic lateral sclerosis (ALS) experience cognitive dysfunction, whilst depression and anxiety are reported in up to 44% and 33%, respectively. These symptoms impact on quality of life, and are associated with a\u00a0poorer prognosis. Historically, outcomes in clinical trials have focused on the effect of candidate drugs on physical functioning.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We reviewed the past 25\u00a0years of clinical trials of investigative medicinal products in people with ALS, since the licensing of riluzole, and extracted data on frequency and type of assessment for neuropsychiatric symptoms and cognitive impairment. Trial registry databases, including WHO International Trials Registry, European Clinical Trials Register, clinicaltrials.gov, and PubMed, were systematically searched for Phase II, III or IV trials registered, completed or published between 01\/01\/1994 and 31\/10\/2019. No language restrictions were applied. Outcome measures, exclusion criteria and assessment tool used were extracted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>216 trials, investigating 26,326 people with ALS, were reviewed. 35% assessed neuropsychiatric symptoms, and 22% assessed cognition, as Exclusion Criteria or Outcome Measures. 3% (<jats:italic>n<\/jats:italic>\u2009=\u20096) of trials assessed neuropsychiatric symptoms as a Secondary Outcome Measure, and 4% (<jats:italic>n<\/jats:italic>\u2009=\u20098) assessed cognition as Outcome Measures; only one trial included assessments for both cognition and neuropsychiatric symptoms as Outcome Measures. Three ALS-specific assessments were used in six trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Trials for people with ALS have neglected the importance of neuropsychiatric symptoms and cognitive impairment. Evaluation of these extra-motor features is essential to understanding the impact of candidate drugs on all symptoms of ALS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>PROPSERO registration<\/jats:title>\n                <jats:p>CRD42020175612.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-020-10203-z","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T14:05:21Z","timestamp":1599746721000},"page":"4510-4521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9843-0778","authenticated-orcid":false,"given":"Emily","family":"Beswick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5715-5025","authenticated-orcid":false,"given":"Arpan R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharthan","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Abrahams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvankar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"issue":"5\u20136","key":"10203_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/17482960802566824","volume":"10","author":"A Chio","year":"2009","unstructured":"Chio A et al (2009) Prognostic factors in ALS: a critical review. Amyotrophic Lateral Sclerosis 10(5\u20136):310\u2013323","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"9","key":"10203_CR2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/j.1468-1331.2007.01843.x","volume":"14","author":"P Wicks","year":"2007","unstructured":"Wicks P et al (2007) Prevalence of depression in a 12-month consecutive sample of patients with ALS. Eur J Neurol 14(9):993\u20131001","journal-title":"Eur J Neurol"},{"key":"10203_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fnins.2019.00175","volume":"13","author":"E Zucchi","year":"2019","unstructured":"Zucchi E, Ticozzi N, Mandrioli J (2019) Psychiatric symptoms in amyotrophic lateral sclerosis: beyond a motor neuron disorder. Front Neurosci 13:19\u201367","journal-title":"Front Neurosci"},{"issue":"2","key":"10203_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1348\/135910799168524","volume":"4","author":"M Johnston","year":"1999","unstructured":"Johnston M et al (1999) Mood as a predictor of disability and survival in patients newly diagnosed with ALS\/MND. Br J Health Psychol 4(2):127\u2013136","journal-title":"Br J Health Psychol"},{"issue":"3","key":"10203_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1136\/jnnp-2019-321737","volume":"91","author":"CA McHutchison","year":"2020","unstructured":"McHutchison CA et al (2020) Relationship between neuropsychiatric disorders and cognitive and behavioural change in MND. J Neurol Neurosurg Psyc 91(3):245\u2013253","journal-title":"J Neurol Neurosurg Psyc"},{"issue":"9","key":"10203_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"H-U Wittchen","year":"2011","unstructured":"Wittchen H-U et al (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(9):655\u2013679","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"10203_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S0006-3223(98)00011-0","volume":"45","author":"MM Ohayon","year":"1999","unstructured":"Ohayon MM et al (1999) The prevalence of depressive disorders in the United Kingdom. Biol Psychiat 45(3):300\u2013307","journal-title":"Biol Psychiat"},{"issue":"1\u20132","key":"10203_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2011.02.023","volume":"132","author":"DC Gon\u00e7alves","year":"2011","unstructured":"Gon\u00e7alves DC, Pachana NA, Byrne GJ (2011) Prevalence and correlates of generalized anxiety disorder among older adults in the Australian National Survey of Mental Health and Well-Being. J Affect Disord 132(1\u20132):223\u2013230","journal-title":"J Affect Disord"},{"key":"10203_CR9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3389\/fnins.2019.00951","volume":"13","author":"S Benbrika","year":"2019","unstructured":"Benbrika S et al (2019) Cognitive, emotional and psychological manifestations in amyotrophic lateral sclerosis at baseline and overtime: a review. Frontiers Neurosci 13:951","journal-title":"Frontiers Neurosci"},{"issue":"4","key":"10203_CR10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S1474-4422(13)70026-7","volume":"12","author":"LH Goldstein","year":"2013","unstructured":"Goldstein LH, Abrahams S (2013) Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 12(4):368\u2013380","journal-title":"Lancet Neurol"},{"issue":"3\u20134","key":"10203_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/21678421.2016.1267768","volume":"18","author":"MJ Strong","year":"2017","unstructured":"Strong MJ et al (2017) Amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyot Lateral Scle Front Degen 18(3\u20134):153\u2013174","journal-title":"Amyot Lateral Scle Front Degen"},{"issue":"6","key":"10203_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S0028-3932(99)00146-3","volume":"38","author":"S Abrahams","year":"2000","unstructured":"Abrahams S et al (2000) Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia 38(6):734\u2013747","journal-title":"Neuropsychologia"},{"issue":"5","key":"10203_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/jnnp-2012-303526","volume":"84","author":"LJ Taylor","year":"2013","unstructured":"Taylor LJ et al (2013) Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 84(5):494\u2013498","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10203_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1037\/a0020357","volume":"25","author":"A Girardi","year":"2011","unstructured":"Girardi A, MacPherson SE, Abrahams S (2011) Deficits in emotional and social cognition in amyotrophic lateral sclerosis. Neuropsychology 25(1):53","journal-title":"Neuropsychology"},{"issue":"6","key":"10203_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/jnnp-2015-310772","volume":"87","author":"R Radakovic","year":"2016","unstructured":"Radakovic R et al (2016) Multidimensional apathy in ALS: validation of the Dimensional Apathy Scale. J Neurol Neurosurg Psychiatry 87(6):663\u2013669","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10203_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.genhosppsych.2006.11.005","volume":"29","author":"W Katon","year":"2007","unstructured":"Katon W, Lin EH, Kroenke K (2007) The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 29(2):147\u2013155","journal-title":"Gen Hosp Psychiatry"},{"issue":"1","key":"10203_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1212\/01.WNL.0000042781.22278.0A","volume":"60","author":"J-S Lou","year":"2003","unstructured":"Lou J-S et al (2003) Fatigue and depression are associated with poor quality of life in ALS. Neurology 60(1):122\u2013123","journal-title":"Neurology"},{"issue":"1","key":"10203_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00415-017-8688-4","volume":"265","author":"J Caga","year":"2018","unstructured":"Caga J et al (2018) Apathy and its impact on patient outcome in amyotrophic lateral sclerosis. J Neurol 265(1):187\u2013193","journal-title":"J Neurol"},{"issue":"5\u20136","key":"10203_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3109\/21678421.2015.1051990","volume":"16","author":"TJ Watermeyer","year":"2015","unstructured":"Watermeyer TJ et al (2015) Impact of disease, cognitive and behavioural factors on caregiver outcome in amyotrophic lateral sclerosis. Amyot Lateral Scler Frontotemp Degen 16(5\u20136):316\u2013323","journal-title":"Amyot Lateral Scler Frontotemp Degen"},{"issue":"5\u20136","key":"10203_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3109\/21678421.2016.1165257","volume":"17","author":"M Bock","year":"2016","unstructured":"Bock M et al (2016) Cognitive-behavioral changes in amyotrophic lateral sclerosis: screening prevalence and impact on patients and caregivers. Amyot Lateral Scler Frontotemp Degen 17(5\u20136):366\u2013373","journal-title":"Amyot Lateral Scler Frontotemp Degen"},{"issue":"6","key":"10203_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1017\/S0033291706007124","volume":"36","author":"L Goldstein","year":"2006","unstructured":"Goldstein L et al (2006) Predictors of psychological distress in carers of people with amyotrophic lateral sclerosis: a longitudinal study. Psychol Med 36(6):865\u2013875","journal-title":"Psychol Med"},{"key":"10203_CR22","first-page":"6","volume":"3","author":"RG Miller","year":"2012","unstructured":"Miller RG (2012) JD Mitchell, DH Moore, Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev 3:6","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10203_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G et al (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330(9):585\u2013591","journal-title":"N Engl J Med"},{"issue":"913","key":"10203_CR24","first-page":"1425","volume":"347","author":"Group II RS","year":"1996","unstructured":"Group II RS (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347(913):1425\u20131431","journal-title":"Lancet"},{"key":"10203_CR25","first-page":"851","volume":"182","author":"N Yanagisawa","year":"1997","unstructured":"Yanagisawa N et al (1997) Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan. Igakuno Ayumi 182:851\u2013866","journal-title":"Igakuno Ayumi"},{"issue":"6","key":"10203_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1358\/dot.2018.54.6.2828189","volume":"54","author":"R Bhandari","year":"2018","unstructured":"Bhandari R, Kuhad A (2018) Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today 54(6):349\u2013360","journal-title":"Drugs Today"},{"key":"10203_CR27","first-page":"8","volume":"3","author":"JM Gregory","year":"2019","unstructured":"Gregory JM et al (2019) Neuronal clusterin expression is associated with cognitive protection in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 3:8","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"10203_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/jnnp-2019-320807","volume":"91","author":"JM Gregory","year":"2020","unstructured":"Gregory JM et al (2020) Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. J Neurol Neurosurg Psychiatry 91(2):149\u2013157","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10203_CR29","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00213-019-5188-5","volume":"236","author":"T Pillinger","year":"2019","unstructured":"Pillinger T et al (2019) Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. Psychopharmacology 236(7):1985\u20131997","journal-title":"Psychopharmacology"},{"issue":"14","key":"10203_CR30","doi-asserted-by":"publisher","first-page":"e1610","DOI":"10.1212\/WNL.0000000000007242","volume":"92","author":"LH Van Den Berg","year":"2019","unstructured":"Van Den Berg LH et al (2019) Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology 92(14):e1610\u2013e1623","journal-title":"Neurology"},{"key":"10203_CR31","first-page":"9","volume":"4","author":"CGCU National","year":"2016","unstructured":"National CGCU (2016) Motor Neurone Disease. Assess Managt 4:9","journal-title":"Assess Managt"},{"issue":"5","key":"10203_CR32","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3109\/17482968.2010.498521","volume":"11","author":"M De Carvalho","year":"2010","unstructured":"De Carvalho M et al (2010) A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyot Lateral Scler Frontotemp Degen 11(5):456\u2013460","journal-title":"Amyot Lateral Scler Frontotemp Degen"},{"issue":"4","key":"10203_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1474-4422(13)70037-1","volume":"12","author":"Group, U.-L.S.","year":"2013","unstructured":"Group, U.-L.S. (2013) Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Neurol 12(4):339\u2013345","journal-title":"The Lancet Neurol"},{"issue":"8","key":"10203_CR34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1212\/01.wnl.0000269676.07319.09","volume":"69","author":"R Miller","year":"2007","unstructured":"Miller R et al (2007) Phase II\/III randomized trial of TCH346 in patients with ALS. Neurology 69(8):776\u2013784","journal-title":"Neurology"},{"issue":"7\u20138","key":"10203_CR35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/21678421.2019.1632899","volume":"20","author":"J Gold","year":"2019","unstructured":"Gold J et al (2019) Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyot Lateral Scler Frontotemp Degen 20(7\u20138):595\u2013604","journal-title":"Amyot Lateral Scler Frontotemp Degen"},{"issue":"1\u20132","key":"10203_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jad.2007.11.012","volume":"109","author":"EM Hammer","year":"2008","unstructured":"Hammer EM et al (2008) Validity of the ALS-Depression-Inventory (ADI-12)\u2014a new screening instrument for depressive disorders in patients with amyotrophic lateral sclerosis. J Affect Disord 109(1\u20132):213\u2013219","journal-title":"J Affect Disord"},{"issue":"6","key":"10203_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT et al (1961) An inventory for measuring depression. Arch Gen Psychiatry 4(6):561\u2013571","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10203_CR38","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/occmed\/kqv043","volume":"65","author":"R Sharp","year":"2015","unstructured":"Sharp R (2015) The Hamilton rating scale for depression. Occup Med 65(4):340\u2013340","journal-title":"Occup Med"},{"key":"10203_CR39","first-page":"1","volume":"2","author":"ME Nilsson","year":"2013","unstructured":"Nilsson ME et al (2013) Columbia\u2013suicide severity rating scale scoring and data analysis guide. CSSRS Scoring 2:1\u201313","journal-title":"CSSRS Scoring"},{"issue":"6","key":"10203_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361\u2013370","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"10203_CR41","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL et al (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12):2308\u20132308","journal-title":"Neurology"},{"issue":"9","key":"10203_CR42","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.6061\/clinics\/2013(09)15","volume":"68","author":"Y-P Wang","year":"2013","unstructured":"Wang Y-P, Gorenstein C (2013) Assessment of depression in medical patients: a systematic review of the utility of the Beck Depression Inventory-II. Clinics 68(9):1274\u20131287","journal-title":"Clinics"},{"issue":"12","key":"10203_CR43","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/1099-1166(200012)15:12<1113::AID-GPS253>3.0.CO;2-Y","volume":"15","author":"P Mottram","year":"2000","unstructured":"Mottram P, Wilson K, Copeland J (2000) Validation of the Hamilton Depression Rating Scale and Montgommery and Asberg Rating Scales in terms of AGECAT depression cases. Internat J Geriat Psych 15(12):1113\u20131119","journal-title":"Internat J Geriat Psych"},{"issue":"1","key":"10203_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1477-7525-9-82","volume":"9","author":"CJ Gibbons","year":"2011","unstructured":"Gibbons CJ et al (2011) Rasch analysis of the hospital anxiety and depression scale (HADS) for use in motor neurone disease. Health Quality life Outcomes 9(1):82","journal-title":"Health Quality life Outcomes"},{"issue":"12","key":"10203_CR45","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K et al (2011) The Columbia-Suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168(12):1266\u20131277","journal-title":"Am J Psychiatry"},{"issue":"9\u201310","key":"10203_CR46","first-page":"66","volume":"11","author":"JM Giddens","year":"2014","unstructured":"Giddens JM, Sheehan KH, Sheehan DV (2014) The Columbia-Suicide Severity Rating Scale (C\u2013SSRS): Has the \u201cgold standard\u201d become a liability? Innov Clin Neurosci 11(9\u201310):66","journal-title":"Innov Clin Neurosci"},{"issue":"2","key":"10203_CR47","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1176\/jnp.12.2.233","volume":"12","author":"DI Kaufer","year":"2000","unstructured":"Kaufer DI et al (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsyc Clin Neurosci 12(2):233\u2013239","journal-title":"J Neuropsyc Clin Neurosci"},{"key":"10203_CR48","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2147\/CIA.S63504","volume":"9","author":"CK Lai","year":"2014","unstructured":"Lai CK (2014) The merits and problems of Neuropsychiatric Inventory as an assessment tool in people with dementia and other neurological disorders. Clin Interv Aging 9:1051","journal-title":"Clin Interv Aging"},{"issue":"3","key":"10203_CR49","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3109\/17482961003727954","volume":"11","author":"SC Woolley","year":"2010","unstructured":"Woolley SC et al (2010) Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS\u2122). Amyot Lateral Scler 11(3):303\u2013311","journal-title":"Amyot Lateral Scler"},{"issue":"1\u20132","key":"10203_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/21678421.2013.805784","volume":"15","author":"S Abrahams","year":"2014","unstructured":"Abrahams S et al (2014) Screening for cognition and behaviour changes in ALS. Amyot Lateral Scler Frontotemp Degen 15(1\u20132):9\u201314","journal-title":"Amyot Lateral Scler Frontotemp Degen"},{"issue":"4","key":"10203_CR51","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS et al (2005) The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695\u2013699","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"10203_CR52","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1212\/01.wnl.0000434309.85312.19","volume":"55","author":"P Mathuranath","year":"2000","unstructured":"Mathuranath P et al (2000) A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology 55(11):1613\u20131620","journal-title":"Neurology"},{"issue":"1\u20132","key":"10203_CR53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3109\/21678421.2014.960873","volume":"16","author":"J Murphy","year":"2015","unstructured":"Murphy J, Ahmed F, Lomen-Hoerth C (2015) The UCSF screening exam effectively screens cognitive and behavioral impairment in patients with ALS. Amyot Lateral ScleR Frontotemp Degen 16(1\u20132):24\u201330","journal-title":"Amyot Lateral ScleR Frontotemp Degen"},{"key":"10203_CR54","volume-title":"The measurement and appraisal of adult intelligence MD","author":"D Wechsler","year":"1958","unstructured":"Wechsler D (1958) The measurement and appraisal of adult intelligence MD. Williams and Wilkins, USA"},{"key":"10203_CR55","volume-title":"The prevalence of multimorbidity and its impact on prognosis in motor neuron disease","author":"S Glasmacher","year":"2020","unstructured":"Glasmacher S (2020) The prevalence of multimorbidity and its impact on prognosis in motor neuron disease. The University of Edinburgh, Edinburgh"},{"issue":"2","key":"10203_CR56","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2217\/nmt.15.1","volume":"5","author":"E Mioshi","year":"2015","unstructured":"Mioshi E, Roberts R, Hornberger M (2015) Neuropsychiatric symptoms and survival in amyotrophic lateral sclerosis: a missing link? Neurodegen Dis Manag 5(2):89\u201391","journal-title":"Neurodegen Dis Manag"},{"issue":"11","key":"10203_CR57","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S1474-4422(07)70265-X","volume":"6","author":"J Phukan","year":"2007","unstructured":"Phukan J, Pender NP, Hardiman O (2007) Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 6(11):994\u20131003","journal-title":"Lancet Neurol"},{"key":"10203_CR58","first-page":"1","volume":"1","author":"F Hodgins","year":"2019","unstructured":"Hodgins F, Mulhern S, Abrahams S (2019) The clinical impact of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) and neuropsychological intervention in routine ALS care. Amyot Lateral Scler Frontotemp Degen 1:1\u20138","journal-title":"Amyot Lateral Scler Frontotemp Degen"},{"issue":"3\u20134","key":"10203_CR59","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3109\/21678421.2015.1030430","volume":"16","author":"E Niven","year":"2015","unstructured":"Niven E et al (2015) Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. Amyot Lateral Scler Frontotemp Degen 16(3\u20134):172\u2013179","journal-title":"Amyot Lateral Scler Frontotemp Degen"},{"issue":"3\u20134","key":"10203_CR60","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/21678421.2013.864312","volume":"15","author":"H Mitsumoto","year":"2014","unstructured":"Mitsumoto H et al (2014) ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyot Lateral Scler Frontotemp Degen 15(3\u20134):192\u2013203","journal-title":"Amyot Lateral Scler Frontotemp Degen"},{"issue":"9","key":"10203_CR61","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1212\/WNL.0000000000002305","volume":"86","author":"J Murphy","year":"2016","unstructured":"Murphy J et al (2016) Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology 86(9):813\u2013820","journal-title":"Neurology"},{"key":"10203_CR62","first-page":"18","volume":"2","author":"S Woolley","year":"2018","unstructured":"Woolley S et al (2018) Longitudinal screening detects cognitive stability and behavioral deterioration in ALS patients. Behav Neurol 2:18","journal-title":"Behav Neurol"},{"issue":"15","key":"10203_CR63","doi-asserted-by":"publisher","first-page":"e1370","DOI":"10.1212\/WNL.0000000000006317","volume":"91","author":"C Crockford","year":"2018","unstructured":"Crockford C et al (2018) ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology 91(15):e1370\u2013e1380","journal-title":"Neurology"},{"issue":"17","key":"10203_CR64","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1212\/WNL.0b013e31828f18ac","volume":"80","author":"M Elamin","year":"2013","unstructured":"Elamin M et al (2013) Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology 80(17):1590\u20131597","journal-title":"Neurology"},{"issue":"7","key":"10203_CR65","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1212\/01.WNL.0000156519.41681.27","volume":"64","author":"S Abrahams","year":"2005","unstructured":"Abrahams S, Leigh P, Goldstein L (2005) Cognitive change in ALS: a prospective study. Neurology 64(7):1222\u20131226","journal-title":"Neurology"},{"issue":"2","key":"10203_CR66","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/17482968.2010.536839","volume":"12","author":"N Atassi","year":"2011","unstructured":"Atassi N et al (2011) Depression in amyotrophic lateral sclerosis. Amyot Lateral Scler 12(2):109\u2013112","journal-title":"Amyot Lateral Scler"},{"issue":"11","key":"10203_CR67","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/gps.1610","volume":"21","author":"E Mioshi","year":"2006","unstructured":"Mioshi E et al (2006) The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Internat J Geriat Psych Life Allied Sci 21(11):1078\u20131085","journal-title":"Internat J Geriat Psych Life Allied Sci"},{"issue":"1\u20132","key":"10203_CR68","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jns.2013.10.038","volume":"336","author":"RA Osborne","year":"2014","unstructured":"Osborne RA et al (2014) Screening for frontal lobe and general cognitive impairment in patients with amyotrophic lateral sclerosis. J Neurol Sci 336(1\u20132):191\u2013196","journal-title":"J Neurol Sci"},{"issue":"4","key":"10203_CR69","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1017\/S1355617700644041","volume":"6","author":"A Kertesz","year":"2000","unstructured":"Kertesz A et al (2000) The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia. J Internat Neuropsychol Soc 6(4):460\u2013468","journal-title":"J Internat Neuropsychol Soc"},{"issue":"5","key":"10203_CR70","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/jnnp.47.5.496","volume":"47","author":"J Dick","year":"1984","unstructured":"Dick J et al (1984) Mini-mental state examination in neurological patients. J Neurol Neurosurg Psychiatry 47(5):496\u2013499","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10203_CR71","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097.https:\/\/doi.org\/10.1371\/journal.pmed1000097","journal-title":"PLoS Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10203-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-10203-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-10203-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T05:04:07Z","timestamp":1635915847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-10203-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":71,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10203"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-10203-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"12 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Professor Carson is a paid editor at Journal of Neurology, Neurosurgery and Psychiatry, and gives independent testimony in Court on a range of neuropsychiatric topics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The authors confirm that this article complies with ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}},{"value":"Supplementary Material Document 1.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}